Proteomic Profile After Intervention With Eplerenone Among Persons With HIV
Open Forum Infectious Diseases, 2026
Murthy A., Kolossváry M., Walpert A., Sanchez E., Abohashem S., Tawakol A., Adler G., Grinspoon S., Srinivasa S.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD Infectious Diseases | Pathophysiology | Plasma |  Olink Target 96 |
Abstract
Background
Persons with human immunodeficiency virus (HIV) well-treated on antiretrovirals have increased arterial inflammation, which can lead to development of atherosclerotic disease. We have previously shown that treatment with eplerenone can significantly reduce arterial inflammation, as measured by target-to-background ratio (TBR) on cardiac 18F-fluorodeoxyglucose positron emission tomography/computed tomography, among people with HIV. The mechanisms by which eplerenone may have treatment effects remain unclear.
Methods
We performed a targeted discovery-based approach to identify a proteomics signature associated with eplerenone treatment that may provide a plausible mechanism for the reduction in arterial inflammation. In an exploratory study, we leveraged analyzable samples from participants who completed the 12-month, placebo-controlled, randomized controlled trial MIRABELLA HIV to evaluate 276 proteins (Olink Target 96 Cardiometabolic, Cardiovascular II, Cardiovascular III), with relevance to cardiovascular and cardiometabolic disease.
Results
We identified 11 proteins that differed in expression between treatment groups. Eight proteins (CDH1, CES1, ADM, IL-4RA, FGF-21, FS, FABP2, Gal-4) decreased and 2 proteins increased (CSTB, MPO) in expression with eplerenone compared to placebo. An increase in expression of IL-27 was prevented among eplerenone-treated versus placebo-treated groups. Changes in TBR of the most diseased segment of the index vessel correlated with changes in 3 of these proteins: CDH1 (ρ = 0.53, P = .02), FGF-21 (ρ = 0.64, P = .003), and Gal-4 (ρ = 0.58, P = .009).
Conclusions
Through this proteomics approach, we discovered that 3 key proteins, CDH1, FGF-21, and Gal-4, are decreased in parallel with reductions in arterial inflammation after treatment with eplerenone. Eplerenone-induced reductions in these proteins, known to be related to inflammation, epithelial barrier disruption, vascular dysfunction, and metabolic dysregulation, provide mechanistic insight into pathways by which eplerenone may improve cardiovascular disease in HIV.
Clinical Trials Registration
NCT02740179.